Cancer risk assessment

Revolutionizing Breast Cancer Risk Assessment: Building the future with Volpara x Lunit

Volpara, a Lunit Company, Secures U.S. Defense Health Agency Contract to Modernize Mammography Services

The Time to Plan for NAPBC’s 2024 Standards is Now

Time for “The Risk Assessment Era”

Jill Martin’s breast cancer diagnosis – what it means for all of us

It’s time to face facts: young women get breast cancer, too

Takeaways from the MTMI breast cancer risk assessment webinar

Essential Elements for Starting a Successful Breast Cancer Risk Program

The year ahead in cancer statistics: Why personalized risk assessment remains so important in cancer care

A Q&A with patient advocate and breast cancer previvor Keri Stephens